|
|
|
|
|
Highlights from the 2022 European Society of Medical Oncology Annual Meeting |
|
|
|
|
|
|
| Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial |
| Robert J. Motzer, MD |
| Robert Motzer presented highly awaited results from the CheckMate 914 trial, examining the role of adjuvant nivolumab and ipilimumab in patients treated with nephrectomy for localized renal cell carcinoma (RCC) at a high risk of relapse. The CheckMate 914 trial of nivolumab and ipilimumab vs placebo as adjuvant therapy in patients with localized RCC at high risk of relapse after nephrectomy did not meet the primary endpoint of DFS. |
|
|
|
|
|
| Mini Oral Session: GU Tumors, Non-Prostate |
|
| Updated Efficacy of Lenvatinib + Pembrolizumab Vs Sunitinib in Patients With Advanced Renal Cell Carcinoma in the Clear Study |
| Camillo G. Porta, MD |
| Camillo Porta provides an updated analysis of the CLEAR trial examining the role of the combination of lenvatinib and pembrolizumab, as compared to sunitinib, as first-line therapy in advanced renal cell carcinoma (aRCC). In the primary analysis, there was significantly improved progression-free survival and overall survival in patients treated with the combination approach. |
|
|
|
|
|
| Efficacy of a Tailored Approach With Nivolumab and Nivolumab/ipilimumab as Immunotherapeutic Boost in Metastatic Renal Cell Carcinoma – Final Results of TITAN-RCC |
| Marc-Oliver Grimm, MD |
| Marc-Oliver Grimm presented the final results of the TITAN-RCC trial, assessing a tailored approach to systemic therapy in patients with metastatic renal cell carcinoma. A combination immune checkpoint inhibitor approach with nivolumab 3 mg/kg + ipilimumab 1 mg/kg (nivo+ipi) is an approved first-line treatment approach in mRCC and intermediate / poor risk disease. However, there is significant toxicity so a tailored approach has been assessed in a number of trials. |
|
|
|
|
|
| Updated Results From the CLEAR Trial and the Final Results of TITAN-RCC Discussion
|
| Kate Young, MD |
| Following presentations from Dr. Camillo Porta discussing updated results from the CLEAR trial on outcomes of the combination of lenvatinib and pembrolizumab as first-line therapy in advanced renal cell carcinoma (RCC) and from Marc-Oliver Grimm discussing a tailored approach using nivolumab either as monotherapy or in combination with ipilimumab in metastatic RCC, Kate Young provided an invited discussion to contextualize these results. |
|
|
|
|
|
|
|
|
|
|
| RACE IT - A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined with ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder
|
| Sebastian Schmid, PD Dr. med.
|
| In the Mini Oral session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on non-prostate genitourinary cancers, Dr. Schmid presented the first results from the RACE IT trial examining the role of neoadjuvant radiotherapy and immunotherapy prior to radical cystectomy in locally advanced bladder cancer.
|
|
|
|
|
|
| First Results from BladderPath: A Randomised Trial of MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer |
| Nicholas James, MBBS, FRCP, FRCR, Ph.D. |
| Nick James presented the first results of the novel BladderPath trial examining the role of magnetic resonance imaging (MRI) for bladder cancer staging. For more than 100 years, transurethral resection of bladder tumour (TURBT) has been the mainstay of bladder cancer staging. These authors believed that image-directed staging may allow for more timely definitive therapy for patients with suspected muscle invasive bladder cancer (MIBC). |
|
|
|
|
|
| Hypoxic Bladder Cancers Have a Poorer Outcome Following Hypofractionated Vs Conventionally Fractionated Radiotherapy in the BC2001 and BCON Randomised Trials |
| Tim A. Smith, MD, Ph.D. |
| Tim Smith presented a post-hoc aggregate analysis of the BC2001 and BCON trials aimed at assessing the effect of tumor hypoxia on radiotherapy fractionation schedules. Standard of care treatment for patients with muscle-invasive bladder cancer (MIBC) includes radical cystectomy or radiotherapy with radiosensitizing systemic therapy. |
|
|
|
|
|
|
|
|
|
|
| A Discussion on Radiation Therapy Before Radical Cystectomy combined with Immunotherapy in Locally Advanced Urothelial Carcinoma, First Results from BladderPath, and BC2001 and BCON Randomised Trials |
| Joaquim Bellmunt, MD, Ph.D. |
| Following presentations from Sebastian Schmid discussing first results from the RACE IT trial examining pre-operative radiotherapy and immunotherapy prior to radical cystectomy, Nick James discussing the role of magnetic resonance imaging (MRI) compared to cystoscopy for bladder cancer staging, and Tim Smith discussing differential outcomes of hypofractionated and conventionally fractionated radiotherapy in patients with hypoxic bladder tumors, Joaquim Bellmunt provided an invited discussion to contextualize these results. |
|
|
|
|
|
| Urothelial Cancer Posters |
|
| Prevalence of PD-L1 High Expression in Advanced Urothelial Carcinoma (aUC): Results from the PREVAIL Prospective Cohort Study |
| Petros Grivas, MD, Ph.D. |
| Petros Grivas presented a poster based on results from the PREVAIL Prospective Cohort Study assessing the prevalence of Programmed death-ligand 1 (PD-L1) high expression in patients with advanced urothelial carcinoma. Dr. Grivas concluded that real-world data suggest a similarly high prevalence of PD-L1 high expression (55%) in patients starting first-line systemic therapy for advanced urothelial carcinoma as has been observed in clinical trials. However, only a quarter of patients had prior PD-L1 testing, which limited inter-assay concordance evaluation. |
|
|
|
|
|
| Phase 2 Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin in Patients (pts) With HER2-Expressing Urothelial Carcinoma (RC48G001, Trial in Progress) |
| Vadim S. Koshkin, MD |
| In the Urothelial Cancer poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Vadim Koshkin presented the rationale and design of a novel trial in progress of Disitamab vedotin (DV; RC48-ADC) is an investigational antibody–drug conjugate (ADC) comprised of a HER2-directed monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a protease-cleavable linker. |
|
|
|
|
|
|
